Transplant-eligible patients with polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome are treated with induction therapy and autologous stem cell transplantation (ASCT). This evidence concerns the gene MYOM2 and polyneuropathy.